Early initiation of menopausal HT reduces all-cause mortality, CHD events in women
Women have a lower risk for all-cause mortality, coronary heart disease and other poor health outcomes with hormone therapy when treatment begins during or close to menopause and continues long term, according to a speaker.
“Menopausal HT is a cost-effective, sex-specific therapy that reduces all-cause mortality; cancer mortality, including breast cancer when treated with estrogen alone; other mortality, including dementia and Alzheimer’s disease; CHD; bone fractures; and new-onset diabetes, with rare risks when initiated around the time of menopause and continued long term,” Howard N. Hodis, MD, the Harry J. Bauer and Dorothy Bauer Rawlins professor of cardiology, professor of medicine and preventive medicine, and director of the atherosclerosis research unit at the University of Southern California, said during a presentation at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease virtual meeting. “The benefits of hormone replacement therapy outweigh the risks when initiated around the time of menopause.”
Read more from Healio about Early initiation of menopausal HT reduces all-cause mortality, CHD events in women